Therapeutics
Funding
NIAID awards investigator-initiated research grants as well as grants and contracts in targeted areas addressed through various program solicitations (e.g., Requests for Applications/Proposals, Program Announcements). Selected targeted programs include:
Description: The Integrated Preclinical/Clinical Program (IPCP) is a grant program that provides a continuous spectrum of research opportunities. IPCP supports research by collaborative groups seeking to transition from preclinical to clinical studies during the award period, as well as pilot clinical studies of novel treatments. This program is designed to promote creative and original therapeutic research on diverse facets of HIV infection between multidisciplinary preclinical and clinical research groups from academic or nonprofit institutions and research firms.
Awardees:
-
William Olson, PI, Progenics, Inc. HIV therapy with CCR5 monoclonal antibody PRO 140 (FY05)
-
Carl June, PI, University of Pennsylvania. Lentivirus-based immunogene therapy for HIV infection (FY05)
-
John Zaia, PI, City of Hope. Lentivirus-based immunotherapy for AIDS (FY04)
-
Prasad, PI, Albert Einstein College of Medicine. Blocking HIV with aptamers targeted to viral components (FY04)
Description: Small Business Innovative Research (SBIR) grants provide incentive for biotechnology industry studies of targeted therapies and drug delivery systems.
Awardees: (Selected awardees working on HIV therapeutic drug discovery and development, funded in FY 05)
-
ViroLogic, Inc. HIV-1 envelope phenotype/genotype database resources
-
BioScale, Inc. Novel viral load diagnostic for resource-limited settings
-
MitoScience, LLC. Mitochondrial dysfunction in HAART: point of care tests
-
Cumberland Pharmaceutical, Inc. and the University of Mississippi Mycotic Research Center. High purity Amphotericin B: a safer antimycotic in AIDS
-
ViroLogic, Inc. Drug susceptibility assay for non-subtype B HIV-1
-
Locus Pharmaceuticals, Inc. Optimization of HIV-1 entry inhibitors targeting gp41
-
Achillion Pharmaceuticals. Capsid assembly inhibitors for the treatment of AIDS
More information on current funding opportunities.
back to top